Dapagliflozin alleviates renal fibrosis in type 2 diabetic mice through regulating STAT3 - PubMed
4 hours ago
- #STAT3
- #Renal Fibrosis
- #Dapagliflozin
- Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, shows therapeutic efficacy in type 2 diabetes.
- The study explores dapagliflozin's effects on renal fibrosis in diabetic mice and renal tubular epithelial cells under hyperglycemic conditions.
- Dapagliflozin treatment reduces fibrosis biomarkers like Matrix Metallopeptidase 2, Transforming Growth Factors 1, phosphorylated Smad2/3, collagen III, and α-smooth muscle actin.
- The antifibrotic effect is linked to dapagliflozin's inhibition of STAT3 phosphorylation and nuclear migration.
- STAT3 knockdown experiments confirm its role in reducing renal fibrosis markers.
- The study highlights dapagliflozin's potential in mitigating diabetes-induced kidney fibrosis by targeting STAT3 activation.